Role of inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease (CAD) patients

Cytokine

Volumn 61, Issue 3, 2013, Pages 856-861

  Mishra, Avshesh ^a   Srivastava, Anshika ^a   Mittal, T ^a   Garg, N ^a   Mittal, B ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Coronary artery disease; Inflammation; LVD; LVEF

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HUMAN; IL6 GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NFKB1 GENE; PRIORITY JOURNAL; TNF ALPHA GENE;

CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DEMOGRAPHY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDEL MUTATION; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, GENETIC; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84875377218     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.12.020     Document Type: Article

References (38)

1. Armstrong P.W. Left ventricular dysfunction: causes natural history and hopes for reversal. Heart 2000, 84(Suppl 1):7-i15. discussion i50.
2. Konstam M.A., Udelson J.E., Anand I.S., Cohn J.N. Ventricular remodeling in heart failure: a credible surrogate endpoint. J Card Fail 2003, 9:350-353.
3. Kawamura N., Kubota T., Kawano S., Monden Y., Feldman A.M., Tsutsui H., et al. Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res 2005, 66:520-529.
4. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 109. II2-10.
5. Baldwin A.S. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001, 107:3-6.
6. Karban A.S., Okazaki T., Panhuysen C.I., Gallegos T., Potter J.J., Bailey-Wilson J.E., et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004, 13:35-45.
7. Santos D.G., Resende M.F., Mill J.G., Mansur A.J., Krieger J.E., Pereira A.C. Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure. BMC Med Genet 2010, 11:89.
8. Castell J.V., Gomez-Lechon M.J., David M., Fabra R., Trullenque R., Heinrich P.C. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990, 12:1179-1186.
9. Sie M.P., Mattace-Raso F.U., Uitterlinden A.G., Arp P.P., Hofman A., Pols H.A., et al. The interleukin-6-174 G/C promoter polymorphism and arterial stiffness; the Rotterdam Study. Vasc Health Risk Manage 2008, 4:863-869.
10. Chrysohoou C., Pitsavos C., Barbetseas J., Kotroyiannis I., Brili S., Vasiliadou K., et al. Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study). Heart Vessels 2009, 24:22-26.
11. Manginas A., Tsiavou A., Chaidaroglou A., Giamouzis G., Degiannis D., Panagiotakos D., et al. Inflammatory cytokine gene variants in coronary artery disease patients in Greece. Coron Artery Dis 2008, 19:575-582.
12. Adamopoulos S., Kolokathis F., Gkouziouta A., Georgiadou P., Chaidaroglou A., Karavolias G.K., et al. Cytokine gene polymorphisms are associated with markers of disease severity and prognosis in patients with idiopathic dilated cardiomyopathy. Cytokine Epub 2011, 54:68-73.
13. Strieter R.M., Kunkel S.L., Bone R.C. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993, 21:63-S447.
14. Bozkurt B., Kribbs S.B., Clubb F.J., Michael L.H., Didenko V.V., Hornsby P.J., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391.
15. Li Y.Y., Feng Y.Q., Kadokami T., McTiernan C.F., Draviam R., Watkins S.C., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000, 97:12746-12751.
16. Jeanmonod P., von Kanel R., Maly F.E., Fischer J.E. Elevated plasma C-reactive protein in chronically distressed subjects who carry the A allele of the TNF-alpha-308 G/A polymorphism. Psychosom Med 2004, 66:501-506.
17. Bernard V., Pillois X., Dubus I., Benchimol D., Labouyrie J.P., Couffinhal T., et al. The -308 G/A tumor necrosis factor-alpha gene dimorphism: a risk factor for unstable angina. Clin Chem Lab Med 2003, 41:511-516.
18. Mishra A., Srivastava A., Mittal T., Garg N., Mittal B. Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clin Chim Acta 2012, 413:1668-1674.
19. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986, 57:450-458.
20. Devlin B., Roeder K. Genomic control for association studies. Biometrics 1999, 55:997-1004.
21. Rickham P.P. Human experimentation. code of ethics of the World Medical Association. Declaration of Helsinki. Br Med J 1964, 2:177.
22. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
23. Johnson R., McNutt P., MacMahon S., Robson R. Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis. Clin Chem 1997, 43:2183-2184.
24. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
25. Ye S., Dhillon S., Ke X., Collins A.R., Day I.N. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 2001, 29:8-E88.
26. Srivastava A., Garg N., Mittal T., Khanna R., Gupta S., Seth P.K., et al. Association of 25 bp deletion in MYBPC3 gene with left ventricle dysfunction in coronary artery disease patients. PLoS One 2011, 6:e24123.
27. Mishra A., Srivastava A., Mittal T., Garg N., Mittal B. Impact of renin-angiotensin-aldosterone system gene polymorphisms on left ventricular dysfunction in coronary artery disease patients. Dis Markers 2012, 32:33-41.
28. Tang W., Devereux R.B., Rao D.C., Oberman A., Hopkins P.N., Kitzman D.W., et al. Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. Am Heart J 2002, 143:854-860.
29. Aggarwal B.B., Shishodia S., Sandur S.K., Pandey M.K., Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol 2006, 72:1605-1621.
30. Oikonomou E., Tousoulis D., Siasos G., Zaromitidou M., Papavassiliou A.G., Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol 2011, 52:30-40.
31. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
32. Birks E.J., Khaghani A., Bowles C., Hunt D., Pepper J.R., Banner N.R., et al. Serum cytokines in left ventricular assist device candidates. Transplant Proc 2001, 33:1974-1975.
33. Fonarow G.C., Peacock W.F., Phillips C.O., Givertz M.M., Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007, 49:1943-1950.
34. Pereira S.G., Oakley F. Nuclear factor-kappaB1: regulation and function. Int J Biochem Cell Biol 2008, 40:1425-1430.
35. Cao S., Zhang X., Edwards J.P., Mosser D.M. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 2006, 281:26041-26050.
36. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
37. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62.
38. Frantz S., Fraccarollo D., Wagner H., Behr T.M., Jung P., Angermann C.E., et al. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003, 57:749-756.